• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

CTI BioPharma - Articles and news items

aml-Tosedostat

Tosedostat in combination with low dose cytarabine achieves primary endpoint in Phase 2 study

Industry news / 15 June 2015 / Victoria White

CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +